Cleveland BioLabs, Inc. (CBLI)
| Market Cap | 76.11M |
| Revenue (ttm) | 262,942 |
| Net Income (ttm) | -2.40M |
| Shares Out | 15.47M |
| EPS (ttm) | -0.19 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | April 22 |
| Last Price | $4.89 |
| Previous Close | $4.95 |
| Change ($) | -0.06 |
| Change (%) | -1.21% |
| Day's Open | 4.95 |
| Day's Range | 4.75 - 5.08 |
| Day's Volume | 89,523 |
| 52-Week Range | 1.43 - 10.97 |
The substantially improved pharmacological profile of GP532 opens new opportunities for broader therapeutic applications of this class of pharmaceuticals BUFFALO, NY / ACCESSWIRE / April 14, 2021 / Geno...
NEW YORK, March 12, 2021 /PRNewswire/ -- If you own shares in any of the companies listed above and would like to discuss our investigations or have any questions concerning this notice or your rights o...
FORT COLLINS, Colo. and BUFFALO, N.Y., Feb. 17, 2021 /PRNewswire/ -- Cleveland BioLabs, Inc. (NASDAQ: CBLI), an innovative biopharmaceutical company developing novel approaches to activate the immune sy...
NEW YORK, Dec. 28, 2020 /PRNewswire/ -- Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies: Cleveland BioLabs, Inc. (NASDAQ: CBLI) concerning pote...
NEW YORK, Oct. 21, 2020 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Cleveland BioLabs, Inc. ("CBLI" or the ...
NEW YORK, Oct. 21, 2020 /PRNewswire/ -- Rowley Law PLLC is investigating potential securities law violations by Cleveland BioLabs, Inc. (NASDAQ: CBLI) and its board of directors concerning the proposed ...
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLP, a global investor rights law firm, is investigating whether the merger between Cleveland BioLabs, Inc. (NASDAQ: CBLI) and Cytocom, Inc. is fair to Cleveland ...
New York, New York--(Newsfile Corp. - October 20, 2020) - The following statement is being issued by Levi & Korsinsky, LLP:To: All Persons or Entities who purchased Cleveland BioLabs, Inc. ("BioLabs" or...
Shares of nano-cap Cleveland BioLabs, Inc. (NASDAQ: CBLI) jumped out of the gate at Monday's open and are sustaining the strong momentum on over 100 times their average volume.
Airlines, hotels, casinos and stocks linked to Wuhan, China, continue to fall as fear of the coronavirus deters international travel and all but halts activity in the virus epicenter.
About CBLI
Cleveland BioLabs, Inc., a biopharmaceutical company, develops novel approaches to activate the immune system and address various medical needs in the United States and Russia. Its proprietary platform of toll-like immune receptor activators (TLR) has applications in mitigation of radiation injury, radiation oncology, and immuno-oncology. The company's product candidate is entolimod, an immune-stimulatory agent, which is used as a medical radiation countermeasure and other indications in radiation oncology. It is also developing Mobilan, a reco... [Read more...]
| Industry Biotechnology | IPO Date Jul 21, 2006 |
| Stock Exchange NASDAQ | Ticker Symbol CBLI |
Financial Performance
In 2020, CBLI's revenue was $262,942, a decrease of -76.38% compared to the previous year's $1.11 million. Losses were -$2.40 million, -9.39% less than in 2019.